Synergistic Internal Ribosomal Entry Site (IRES)—MicroRNA-Based Approach for Attenuation of Flaviviruses and Live Vaccine Development

Many members of the Flaviviridae family are emerging and reemerging human pathogens that have caused outbreaks of devastating and often fatal diseases and represent a serious public health problem on a global scale. There is no single attenuation strategy that exists which is sufficient to prepare a safe, efficacious and immunogenic live attenuated virus vaccine that will work universally for Flaviviridae. This patent application claims live attenuated flavivirus vaccines, live attenuated multivalent flavivirus vaccines, and methods of preventing flavivirus infections as well as methods of making the vaccines claimed in the application. More specifically, this patent application claims methods for attenuating a flavivirus or chimeric flavivirus using a synergistic dual strategy involving inserting miRNA-targeting sequences to restrict virus replication in target hosts, cells and/or tissues and placing one or more flavivirus genes under translational control of an internal ribosomal entry site (IRES).

Potential Commercial Applications: Competitive Advantages:
  • Diagnostics
  • Vaccines
  • Potential one-dose flavivirus vaccine
  • Ease of manufacture in Vero cells
  • Low-cost potential vaccine
  • Developing and developed world potential vaccines


Alexander Pletnev (NIAID)  ➽ more inventions...

Konstantin Tsetsarkin (NIAID)  ➽ more inventions...

Intellectual Property:
US Application No. 62/443,214
PCT Application No. PCT/US2018/012346

Collaboration Opportunity:

The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize vaccine(s) for prophylaxis against flavivirus infections. For collaboration opportunities, please contact Peter Soukas, J.D. at or 301-594-8730.

Licensing Contact:
Peter Soukas, J.D.
Phone: 301-496-2644

OTT Reference No: E-006-2017-0
Updated: Mar 1, 2017